摘要
目的：比较恩替卡韦（ETV）与替诺福韦酯（TDF）初始治疗慢性乙型肝炎（CHB）患者的疗效和安全性。方法选择52例 CHB 患者52例，采用数字表法随机分为 ETV 组（26例）和 TDF 组（26例），两组治疗后4周、8周、12周、24周、36周、48周、72周、96周分别检测乙型肝炎病毒血清学标志物、HBV DNA 水平及血清丙氨酸氨基转移酶（ALT），并观察药物的安全性。结果两组患者临床特征差异无统计学意义；ETV 组早期病毒学应答率低于 TDF 组（8周，23．1％比50．0％，χ2＝4．266，P ＝0．045），但两组远期病毒学应答率（12～96周）差异均无统计学意义（均 P ＞0．05）；两组治疗后，血清 HBeAg 转阴率差异无统计学意义（均 P ＞0．05）；两种药物均未见明显不良反应。结论总体来说，ETV 和 TDF 抗病毒效果及安全性相当。
Objective To compare the effects and safety of entecavir（ETV）and tenofovir disoproxil fumar-ate（TDF）in initial treatment of patients with chronic hepatitis B virus infection.Methods 52 chronic HBV infection cases were randomly divided into initially treated with tenofovir（TDF group）or entecavir（ETV group）in this retro-spective study.The following parameters were assessed：HBeAg status,serum alanine aminotransferase （ALT）,and HBV -DNA levels at weeks 4,8,12,24,36,48,72,and 96;total duration of follow -up and adverse reactions. Results The clinical characteristics of two groups had no statistically significant difference.At 8 weeks,the response rate was significantly higher in the TDF group than in ETV group（23.1% vs.50.0%,？2 =4.266,P =0.045）.Less patients administered ETV showed undetectable HBV -DNA levels compared with the TDF group in late treatment （weeks 12 -96）,the differences were not statistically significant （all P 〉0.05）,as well as HBeAg seroconversion rate（all P 〉0.05）.No adverse reactions were found.Conclusion ETV and TDF are comparable in efficacy and safety to suppress HBV -DNA replication in CHB patients.
作者
李国涛
臧珂
Li Guotao Zang Ke.(Department of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, He＇ nan 471000, China)
出处
《中国基层医药》
CAS
2016年第24期3790-3793,I0005,共5页
Chinese Journal of Primary Medicine and Pharmacy
关键词
肝炎
乙型
慢性
恩替卡韦
替诺福韦酯
Hepatitis,type B,chronic
Entecavir
Tenofovir disoproxil fumarate
